Comparability of input parameters in the German Retina.net ROP registry and the EU-ROP registry - An exemplary comparison between 2011 and 2021
© 2023 The Authors. Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation..
PURPOSE: The German Retina.net ROP registry and its Europe-wide successor, the EU-ROP registry, collect data from patients treated for ROP. This analysis compares input parameters of these two registries to establish a procedure for joint analyses of different registry data using exemplary datasets from the two registries.
METHODS: Exemplary datasets from the two databases over a 1-year period each (German Retina.net ROP Registry, 2011, 22 infants; EU-ROP Registry, 2021, 44 infants) were compared. The parameters documented in the two databases were aligned and analysed regarding demographic parameters, treatment modalities, complications within first 24 h and retreatments.
RESULTS: The current analysis showed that data can be aligned for joint analyses with some adjustments within the data structure. The registry with more detailed data collection (EU-ROP) needs to be reduced regarding granularity in order to align the different registries, as the registry with lower granularity determines the level of analyses that can be performed in a comparative approach. In the exemplary datasets, we observed that the overall most common ROP severity in both registries was zone II, 3+ (2011: 70.5%; 2021: 65%), with decreasing numbers of clock hours showing preretinal neovascularisations (2011: 10-12 clock hours in 29% of cases, 2021: 4-6 clock hours in 38%). The most prevalent treatment method was laser coagulation in 2011 (75%) and anti-VEGF therapy in 2021 (86.1%). Within the anti-VEGF group, all patients were treated with bevacizumab in 2011 and with ranibizumab in 2021. Retreatment rates were comparable in 2011 and 2021.
CONCLUSION: Data from two different ROP registries can be aligned and jointly analysed. The analysis reveals a paradigm shift in treatment modalities, from predominantly laser to anti-VEGF, and within the anti-VEGF group from bevacizumab to ranibizumab in Germany. In addition, there was a trend towards earlier treatment in 2021.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:102 |
|---|---|
| Enthalten in: |
Acta ophthalmologica - 102(2024), 3 vom: 25. Apr., Seite e314-e321 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Winter, K [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 10.04.2024 Date Revised 10.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/aos.15753 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362218749 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362218749 | ||
| 003 | DE-627 | ||
| 005 | 20240410232220.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/aos.15753 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1371.xml |
| 035 | |a (DE-627)NLM362218749 | ||
| 035 | |a (NLM)37725047 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Winter, K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparability of input parameters in the German Retina.net ROP registry and the EU-ROP registry - An exemplary comparison between 2011 and 2021 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.04.2024 | ||
| 500 | |a Date Revised 10.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation. | ||
| 520 | |a PURPOSE: The German Retina.net ROP registry and its Europe-wide successor, the EU-ROP registry, collect data from patients treated for ROP. This analysis compares input parameters of these two registries to establish a procedure for joint analyses of different registry data using exemplary datasets from the two registries | ||
| 520 | |a METHODS: Exemplary datasets from the two databases over a 1-year period each (German Retina.net ROP Registry, 2011, 22 infants; EU-ROP Registry, 2021, 44 infants) were compared. The parameters documented in the two databases were aligned and analysed regarding demographic parameters, treatment modalities, complications within first 24 h and retreatments | ||
| 520 | |a RESULTS: The current analysis showed that data can be aligned for joint analyses with some adjustments within the data structure. The registry with more detailed data collection (EU-ROP) needs to be reduced regarding granularity in order to align the different registries, as the registry with lower granularity determines the level of analyses that can be performed in a comparative approach. In the exemplary datasets, we observed that the overall most common ROP severity in both registries was zone II, 3+ (2011: 70.5%; 2021: 65%), with decreasing numbers of clock hours showing preretinal neovascularisations (2011: 10-12 clock hours in 29% of cases, 2021: 4-6 clock hours in 38%). The most prevalent treatment method was laser coagulation in 2011 (75%) and anti-VEGF therapy in 2021 (86.1%). Within the anti-VEGF group, all patients were treated with bevacizumab in 2011 and with ranibizumab in 2021. Retreatment rates were comparable in 2011 and 2021 | ||
| 520 | |a CONCLUSION: Data from two different ROP registries can be aligned and jointly analysed. The analysis reveals a paradigm shift in treatment modalities, from predominantly laser to anti-VEGF, and within the anti-VEGF group from bevacizumab to ranibizumab in Germany. In addition, there was a trend towards earlier treatment in 2021 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ROP | |
| 650 | 4 | |a anti‐VEGF | |
| 650 | 4 | |a laser coagulation | |
| 650 | 4 | |a observational study | |
| 650 | 4 | |a registry | |
| 650 | 4 | |a retinopathy of prematurity | |
| 650 | 7 | |a Bevacizumab |2 NLM | |
| 650 | 7 | |a 2S9ZZM9Q9V |2 NLM | |
| 650 | 7 | |a Ranibizumab |2 NLM | |
| 650 | 7 | |a ZL1R02VT79 |2 NLM | |
| 650 | 7 | |a Angiogenesis Inhibitors |2 NLM | |
| 650 | 7 | |a Vascular Endothelial Growth Factor A |2 NLM | |
| 700 | 1 | |a Pfeil, J M |e verfasserin |4 aut | |
| 700 | 1 | |a Engmann, H |e verfasserin |4 aut | |
| 700 | 1 | |a Aisenbrey, S |e verfasserin |4 aut | |
| 700 | 1 | |a Lorenz, B |e verfasserin |4 aut | |
| 700 | 1 | |a Hufendiek, K |e verfasserin |4 aut | |
| 700 | 1 | |a Breuss, H |e verfasserin |4 aut | |
| 700 | 1 | |a Khattab, M |e verfasserin |4 aut | |
| 700 | 1 | |a Süsskind, D |e verfasserin |4 aut | |
| 700 | 1 | |a Kakkassery, V |e verfasserin |4 aut | |
| 700 | 1 | |a Lagrèze, W A |e verfasserin |4 aut | |
| 700 | 1 | |a Barth, T |e verfasserin |4 aut | |
| 700 | 1 | |a Liegl, R |e verfasserin |4 aut | |
| 700 | 1 | |a Bründer, M C |e verfasserin |4 aut | |
| 700 | 1 | |a Skevas, C |e verfasserin |4 aut | |
| 700 | 1 | |a Goldammer, I |e verfasserin |4 aut | |
| 700 | 1 | |a Glitz, B |e verfasserin |4 aut | |
| 700 | 1 | |a Michalewicz, E |e verfasserin |4 aut | |
| 700 | 1 | |a Krohne, T U |e verfasserin |4 aut | |
| 700 | 1 | |a Bartmann, I R |e verfasserin |4 aut | |
| 700 | 1 | |a Stahl, A |e verfasserin |4 aut | |
| 700 | 0 | |a Retina.net ROP and EU‐ROP registry study groups |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta ophthalmologica |d 2008 |g 102(2024), 3 vom: 25. Apr., Seite e314-e321 |w (DE-627)NLM171266315 |x 1755-3768 |7 nnns |
| 773 | 1 | 8 | |g volume:102 |g year:2024 |g number:3 |g day:25 |g month:04 |g pages:e314-e321 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/aos.15753 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 102 |j 2024 |e 3 |b 25 |c 04 |h e314-e321 | ||